

****New release July 2010****

MarketVIEW: Norovirus vaccines (CAT: VAMV015)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	MarketVIEW: Norovirus vaccines – Global market forecast
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Novel/travel vaccines</i>
Product (if applicable)	:	CAT No: VAMV015, published July 2010

Background

Noroviruses (NVs) called “Norwalk-like viruses” are a group of single-stranded positive sense RNA viruses and members of the family *Caliciviridae*. NVs are transmitted from human-to-human and are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms usually resolving after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge. In the US, which does not yet have active national surveillance, norovirus infections may account for 235,000 clinic visits, 91,000 emergency room visits and 23,000 hospitalizations among children <5 years of age. There is also evidence that norovirus epidemics are growing in magnitude, severity and in the elderly population, may even be causing fatalities. NV outbreaks are also a well known issue for military installations and commercial cruise ship liners.

A key question for vaccine manufacturers is whether norovirus will be the next rotavirus, and so a commercial opportunity for future development. Presently there is only one known norovirus active program being developed by Montana-based Ligocyte who acquired intellectual property (IP) from Baylor College of Medicine and are supported by the U.S. Army Medical Research and Material Command.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Norovirus across major Western and emerging markets to 2030. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. **LO/BASE/Hi** forecast scenarios are included based upon the level of populations targeted by a potential vaccine.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to norovirus epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of travel and nosocomial vaccines has also been utilised.

PRODUCT CONTENTS:

Published July 2010 (CAT No: VAMV015)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Author's note
Executive Summary
Total predicted demand (000s doses): norovirus vaccine (all scenarios)
Total available market (\$ USD 000s): norovirus vaccine (all scenarios)
Norovirus vaccine – segment value analysis (\$ USD 000s)
Norovirus key disease trends and dynamics
Norovirus vaccine opportunity: target product profile (TPP)
Overall commercial model assumptions: military/stockpile/HCWs/cruise ships
Population segments included in model (scenario definition)
Commercial model assumptions by country: pricing/penetration/compliance
Norovirus vaccine pipeline
Ligocyte VLP vaccine – estimated filing dates per indication
Backup material – methodology
Bibliography
About VacZine Analytics
Disclaimer

PAGES: 30 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Scenario definitions
Total CHARTS
CHARTS – LO/BASE/HI value
CHARTS – LO/BASE/HI volume
VALUE SUMMARY – total market
VOLUME SUMMARY – total market
US lo/base/hi
Canada lo/base/hi
UK lo/base/hi
France lo/base/hi
Germany lo/base/hi

Contents – Vaccine demand model (MS Excel-based) - continued

Italy lo/base/hi
Spain lo/base/hi
EU other lo/base/hi
Japan lo/base/hi
Australia lo/base/hi
Per country vaccine target populations
Source material
Assumptions
Health Care Workers (HCWs)
Uptake case study analysis – per vaccine segment
Germany – norovirus epidemiology
Disclaimer
BACK PAGE

WORKSHEETS: ~45

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$7995.00/ GBP £5499.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 17.5% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. German Federal Health Monitoring. Notifiable Diseases. Available at: <http://www.gbe-bund.de>. Accessed: June 2010
2. Health Protection Agency. Hospital Norovirus Outbreak Reporting. Available at: www.hpa-bioinformatics.org.uk/. Accessed: June 2010
3. Lopman BA et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. *Emerg Infect Dis* 10: 1827-1834.
4. National Advisory Committee on Immunization. Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine. Available at: <http://www.phac-aspc.gc.ca/>. Accessed: June 2010
5. Bailey MS et al. Viral gastroenteritis outbreaks in deployed British troops during 2002-7. *J R Army Med Corps*. 2008 Sep;154(3):156-9.
6. Norwalk Vaccine Study. Available at: <http://clinicaltrials.gov>. Accessed June 2010.
7. Cruise Lines International Association. Available at: <http://www.cruising.org/about-clia>. Accessed: June 2010.
8. National Center for Health Statistics Health, United States, 2008 With Chartbook Hyattsville, MD: 2009. Table 107. Nursing home residents 65 years of age and over, by age, sex, and race: United States, selected years 1973–2004.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926

E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009